Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100,888,000
  • Shares Outstanding, K 2,479,430
  • Annual Sales, $ 38,904 M
  • Annual Income, $ 1,974 M
  • 36-Month Beta 0.82
  • Price/Sales 2.59
  • Price/Cash Flow 10.60
  • Price/Book 20.19

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.44 +6.16%
on 06/28/18
42.32 -1.06%
on 07/20/18
+0.84 (+2.05%)
since 06/20/18
3-Month
38.90 +7.62%
on 04/25/18
42.36 -1.16%
on 06/14/18
+1.87 (+4.67%)
since 04/20/18
52-Week
34.52 +21.29%
on 12/06/17
42.83 -2.24%
on 07/21/17
-0.90 (-2.10%)
since 07/20/17

Most Recent Stories

More News
Novartis' (NVS) Kisqali Gets FDA Nod for Label Expansion

Novartis' (NVS) breast cancer drug, Kisqali, gets FDA approval as first-line treatment for pre-, peri- or post-menopausal women with HR+/HER2- advanced breast cancer.

ONCE : 81.25 (-1.01%)
NVS : 82.27 (+1.82%)
RHHBY : 29.4700 (+1.94%)
GSK : 41.87 (+2.90%)
NeuroMetrix Reports Q2 2018 Financial Results

NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended June 30, 2018.

NURO : 1.27 (unch)
GSK : 41.87 (+2.90%)
J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod

The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.

ILMN : 311.15 (+0.66%)
JNJ : 125.85 (-0.07%)
GILD : 77.37 (+0.42%)
GSK : 41.87 (+2.90%)
Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto

Novartis (NVS) misses on Q2 earnings but beats sales on the back of continued momentum from Cosentyx and Entresto. Oncology franchise also exhibits strong growth.

ONCE : 81.25 (-1.01%)
NVS : 82.27 (+1.82%)
AMGN : 190.49 (-0.66%)
GSK : 41.87 (+2.90%)
Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced favorable review of safety data from the second dose cohort of patients who received one billion...

ADAP : 10.44 (-4.92%)
GSK : 41.87 (+2.90%)
Adult Vaccine Market: Global Analysis by Disease & Companies to 2024 - Featuring Leading Players GlaxoSmithKline, Merck, Sanofi and Pfizer - ResearchAndMarkets.com

The "Adult Vaccine Market, Global Analysis By Disease (Influenza, Cervical Cancer, Zoster, MMR , Pneumonia, Meningitis, Hepatitis, Tap , Varicella & Travel & Miscellaneous Vaccine)...

MRK : 62.52 (+0.02%)
GSK : 41.87 (+2.90%)
Is a Surprise in the Cards for Novartis in Q2 Earnings?

Swiss-giant Novartis (NVS) is all set to report second-quarter 2018 earnings on Jul 18. While the pharma business should maintain growth, the generic division is expected to be laggard.

ONCE : 81.25 (-1.01%)
NVS : 82.27 (+1.82%)
AMGN : 190.49 (-0.66%)
GSK : 41.87 (+2.90%)
Pfizer (PFE) to Reorganize Business Into Three New Units

Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.

JNJ : 125.85 (-0.07%)
MRK : 62.52 (+0.02%)
PFE : 37.33 (-0.08%)
GSK : 41.87 (+2.90%)
Merck's Keytruda Gets FDA's Priority Review for Liver Cancer

The FDA grants a priority review to Merck's (MRK) label expansion filing for its key cancer drug Keytruda regarding the first-line treatment of advanced HCC.

MRK : 62.52 (+0.02%)
AMGN : 190.49 (-0.66%)
PFE : 37.33 (-0.08%)
GSK : 41.87 (+2.90%)
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs

Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.

AZN : 37.17 (+0.38%)
JNJ : 125.85 (-0.07%)
MRK : 62.52 (+0.02%)
ADMP : 3.80 (+4.11%)
NVS : 82.27 (+1.82%)
GSK : 41.87 (+2.90%)
BMY : 56.71 (+0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade GSK with:

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

2nd Resistance Point 43.41
1st Resistance Point 42.64
Last Price 41.87
1st Support Level 40.78
2nd Support Level 39.69

See More

52-Week High 42.83
Last Price 41.87
Fibonacci 61.8% 39.66
Fibonacci 50% 38.68
Fibonacci 38.2% 37.69
52-Week Low 34.52

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar